Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Solid connections for solid revenues! Gotta love it!
The report also said: “Allergenex is a trade name of Spiriplex, Inc.” at the bottom.
Peer review? I’d say...
“Arrayit president Dr Mark Schena signs three-year extension to the editorial board of the prestigious scientific journal Current Genomics published by Bentham Science and featuring the latest high-tech advances in the $20 billion worldwide genomics market current-genomics.com”
FYI This is a photo demonstration of the left hand of Arrayit Corporation's CFO - Rene` Schena. Nice job!
— Sucedia (@ForSucedia) January 16, 2019
From Suzanne Martinsky, Todd’s wife...
She refers to Rene as CFO...
Could she be holding both positions?
Not under normal circumstances...but this IS a small company.
FYI This is a photo demonstration of the left hand of Arrayit Corporation's CFO - Rene` Schena. Nice job!
— Sucedia (@ForSucedia) January 16, 2019
Kaiser...be still my beating heart!
All from our little ol' CE company. Don't you love it!
What is a client service manual?
"A customer service training manual serves as an invaluable tool for instructing your employees how to best provide top-quality service to your clients or customers. A comprehensive training manual addresses common customer concerns and internal policies that cover how you want your employees to handle issues related to product returns, complaints and service issues. For best results, create a document that can be used for live training as well as a reference guide."
https://smallbusiness.chron.com/produce-customer-service-training-manual-39400.html
This should have been a tweet. Not a press release. This is not substitutive enough information to warrant a press release.
A father/daughter, family practice. Maybe five hundred patients if they're lucky...
They don't run in big circles. She's been part of one paper written regarding non-english-speaking patients.
I don't enjoy being Debbie Downer. Just calling it as I see it.
It's my belief the portal sign-ups are really helping move the share price. It was a good week.
I've rarely seen L2 trading this even ...
They have...four times.
"We will be listing on Nasdaq with the current outstanding share count."
Gotta love it!
https://patents.google.com/patent/US6913879B1/en?assignee=TeleChem+International+Inc
"More generally, the method would allow multiple samples from any source of human, animal, plant, or microbial material to be screened for alleles at multiple genetic loci in a single assay."
J.P. Morgan Healthcare Conference kicks off Monday with focus on Trump, Amazon
Health care’s biggest annual gathering — the J.P. Morgan Healthcare Conference — starts Monday in San Francisco as the industry grapples with threats from Washington to Silicon Valley.
More than 485 companies from biotech, pharma, insurance, hospital systems and more will give investor presentations to more than 9,000 attendees at the Westin St. Francis hotel this year. Even more consulting companies and law firms will flood hotel suites and conference rooms near Union Square to host meetings that executives compare to speed dating for investors.
In its 37th year, the four-day conference has helped shape the agenda for both the industry and individual companies for the year. Some executives share their financial forecasts or milestones investors can expect from drug pipelines. Others touch on themes for the industry, with tax reform being a major focus last year.
https://www.cnbc.com/2019/01/04/jp-morgan-healthcare-conference-comes-with-focus-on-trump-amazon.html
"Arrayit business development team reports business expansion meeting invitation from a top partner from Buck Consultants International BCI Global on January 7-10 2019 at the prestigious JP Morgan Healthcare Conference in San Francisco California USA https://www.jpmorgan.com/global/healthcareconference …"
We're on week 36 if you count all the weeks of May.
I'm guessing becoming current and uplisting all at the same time...first part of January, 2019.
My money is not being held "hostage". I invested it with Arrayit free and clear, to grow the business.
They're doing with it exactly what they are supposed to be doing with it.
Patience....
With the new testing distributorships (ie. Pinnertest, etc.) adding this in as a choice would be a no-brainer.
This "new" test can only be detected after a tumor exists whereas Arrayit's test is pre-symptomatic.
I would hope that Dr. Mark can refine this process into his micro-arrays.
uhhh...competition?
Blood test can detect cancer in 10 minutes, researchers claim
A simple blood test has been developed that can diagnose cancer in just 10 minutes. It spots tiny amounts of DNA floating through vessels that could only have come from tumors - and not healthy cells.
The breakthrough could lead to much earlier detection and more chance of a cure - with treatment beginning even years before symptoms develop.
It is hoped it will eventually be performed at the same time as routine blood tests, such as a cholesterol check - even using a mobile phone app.
Corresponding author Professor Matt Trau, of the University of Queensland, Brisbane, said it may be the "Holy Grail" of cancer diagnostics.
https://www.foxnews.com/health/blood-test-can-detect-cancer-in-10-minutes-researchers-claim
Didn't take long to create over 4 million in inventory. Multiply that times the rest of the year...
These are the money-makers: World's 10 biggest healthcare companies by revenue.
8. Kaiser Permanente (Oakland, Calif.) – $72.7 billion
Kaiser Permanente reported a 12.5 percent increase in revenues compared to 2016.
https://www.beckersasc.com/leadership-management/these-are-the-money-makers-world-s-10-biggest-healthcare-companies-by-revenue.html
The 10 largest health insurance companies by membership.
8. Kaiser Permanente, 10.7 million members
https://www.beckersasc.com/asc-coding-billing-and-collections/the-10-largest-health-insurance-companies-by-membership.html
2017 Healthcare companies w/over $35b in revs...
https://docs.google.com/spreadsheets/d/1X7-NPrOJXPMt2i2dIMkMFTrQ0208wvCyuEk84RJebRk/edit#gid=847270345
I wonder if they're going to open the market one day next week.
SEC Says Social Media OK for Company Announcements if Investors Are Alerted
FOR IMMEDIATE RELEASE
2013-51
Washington, D.C., April 2, 2013 —
The Securities and Exchange Commission today issued a report that makes clear that companies can use social media outlets like Facebook and Twitter to announce key information in compliance with Regulation Fair Disclosure (Regulation FD) so long as investors have been alerted about which social media will be used to disseminate such information.
https://www.sec.gov/news/press-release/2013-2013-51htm
Solution to the Challenge
Arrayit has developed and patented the world’s finest platform for analyzing DNA, mRNA and protein molecules found in the human body. The Arrayit platform uses a revolutionary device known as a microarray (see Figure 1). Arrayit microarrays are glass substrates that contain DNA spots representing all 25,000 genes in the human genome (blueprint). An Arrayit microarray functions like a biological computer chip, rapidly computing information about each gene in the human body. Patient DNA, mRNA or protein molecules are obtained from a tissue sample such as small amount of human blood. The samples are labeled with fluorescent tags and mixed with a microarray to allow binding of each spot on the microarray with fluorescent molecules in the patient sample. Molecular interactions between the microarray spots and patient molecules cause each spot on the microarray to glow with an intensity consistent with the amount of DNA, mRNA or protein present in the sample. High-speed scanning of the fluorescent microarray provides quantitative data for every gene in the human body in about 5 minutes.
Arrayit Advantage
The Arrayit platform including the company’s Variation Identification Platform™ (VIP) technology provides medically important information rapidly and at a low cost for a large number of patients. Arrayit has the market’s only comprehensive cost-effective solution for population-wide patient screening of DNA, RNA and protein samples for medical decision making. Cost, ease-of-use, flexibility, precision, speed and throughput combine to provide a competitive advantage for Arrayit in the marketplace.
http://www.arrayit.com/Microarray_Investor/Arrayit_Technology/arrayit_technology.html
SEC filing date guideline...
Late Filing Reports: A notification of the inability to timely file all or any portion of a Report on Form 10-K,
10-Q, 20-F or 11-K must be filed by 5:30 p.m. Eastern Time no later than the next business day after the original
due date (Securities Exchange Act Rule 12b-25).
EDGAR Hours of Operation: EDGAR filings may be made from 6:00 a.m. to 10:00 p.m. Eastern Time on weekdays
(excluding federal holidays). Filings submitted after 5:30 p.m. Eastern Time receive the next business day’s filing date
(except Section 16 filings and filings pursuant to Rule 462(b), which receive the actual date of filing).
https://www.mayerbrown.com/files/Publication/137b825c-cd32-4f02-955c-8fa3a67dae46/Presentation/PublicationAttachment/53758b7e-6b23-4991-b36c-b23be1580b77/Draft-Update-2018-SEC-Dates_V7.pdf
I know I have to be careful reading into what he said, but it sounds like he's quite confident.
Very cool..."We are very excited to have united the Allergy Labs of America and AllergyPro models to be able to offer a comprehensive allergy solution for your providers throughout the country. This new partnership affords your doctors a wide range of allergy solutions that can only be found at LabPharm!"
"Doctors are different. Specialties are different. This is why AllergyPro has created three platforms for doctors to choose from. The following criteria allows a doctor decide which platform is best for his practice:
1. Patient volume: Daily volume vs Allergy Volume
2. Payer mix: Commercial, Federal, Cash
3. Level of involvement desired (comfort level vs revenue)
4. Level of revenue to be generated (very low to very high)
5. Patient Outcomes: Being in control of your own patient
All of the AllergyPro platforms provide better allergy and asthma care beyond “symptomatic control”. Each platform is designed to provide both testing and therapy as a combined solution to enhance patient care and build a higher quality of life for patients suffering from allergies.
These must be Arrayit's tests...
"The agency is taking steps to improve our response times and provide actionable information to consumers as quickly as possible."
"As a next step, the FDA plans to collect and analyze romaine lettuce samples through a new special surveillance sampling assignment for contamination with human pathogens."
Awesome follow up. Thank you.
Wow... Us Business News tweet
Todd Martinsky bio from 2009 "Microarray Methods and Protocols"
https://books.google.com/books?hl=en&lr=&id=BjlPbZls-o0C&oi=fnd&pg=PP1&dq=arrayit+microarray&ots=LhHrB69qZm&sig=dOrTBjYLDuGhh5dg5Yxo8bJMiEQ#v=onepage&q=arrayit&f=false
Yes, then I'd have only $1,000,000.00...
Bioprinting verifies bacteria behaviour models
03 Oct 2018 Liam Stubbington
A US research collaboration has successfully adapted an Arrayit Spotbot, usually used to monitor protein activity, to print bacteria. In doing so, the researchers have delivered an experimental platform for testing computational models of communal microbial behaviour on unprecedented small scales (Biomed. Phys. Eng. Express 4 055010).
Bioprinting is a type of 3D printing that uses cells or other biomaterials instead of ink to create biological structures. William Hynes, from SUNY Polytechnic Institute and Lawrence Livermore National Laboratory, and colleagues used the protein microarray machine to position small bacterial colonies in growth medium with high precision.
Traditional cell culture methods have not thus far provided the necessary control of the spatial distribution of cells to test predictive models of microbial interactions. This has hindered the study of communication between bacterial colonies, which underpins behaviours such as biofilm development and diffusion-based metabolite sharing.
The researchers used their novel experimental set-up to validate the computational predictions of a bacterial growth model, Computation of Microbial Ecosystems in Time and Space (COMETS). COMETS estimates the biomass of a bacterial colony as a function of time by balancing the internal cell metabolism with the external flux of metabolites. It has been tested experimentally on the macro scale, but not on the small scale used in this study.
The team used two strains of bacteria, Salmonella enterica (S. Enterica) and an Escherichia coli (E. Coli) mutant, that depend upon one another for the production of metabolites in a growth medium devoid of specific chemicals. In a control experiment, the individual strains showed little or no growth in isolation.
Each colony was made to express a fluorescent protein. The researchers showed that microbial biomass was approximately proportional to the fluorescence intensity in the imaging volume. They used this as a means of measuring bacterial biomass in vitro.
Hynes and colleagues first used the COMETS software to predict the growth of microbial biomass as a function of the separation of the two partner colonies, with colony separation varying from 1–3.5 mm. Such separations are much smaller than those used in experiments prior to this work. The research team reported good qualitative agreement between the simulation and experiment in this scenario.
The group then investigated a more complex “eclipse” scenario, in which a competitor bacterial colony is placed between the two partner colonies. The competitor was chosen to compete directly with either one of the partner colonies or with both. The team then varied the position of the competitor colony to generate different eclipse scenarios for validation.
In these more complicated scenarios, the team reported encouraging results with respect to the general trends of in silico modelling versus in vitro experiments. However, the data possess some notable disparity, including a consistent overshoot in simulations of the relative growth of E. coli, in most scenarios.
This work highlights the importance of seeking a means of validating computational models of bacterial growth across multiple length scales. It also demonstrated that bioprinting could provide a means of achieving this.
The versatility of the ArrayIt Spotbot is not limited to tightly controlling the positioning of small bacterial colonies on growth media. “For my work in developing a diagnostic assay to detect Lyme disease, the robotic pin spotter (Spotbot) is useful for making highly multiplexed protein microarrays on different surfaces,” says Eunice Chou, a PhD student working under Nathaniel Cady at SUNY Polytechnic Institute. “Here, I am using a gold-coated silicon chip, which I spot with various proteins present on the surface of Lyme disease bacteria.”
https://physicsworld.com/a/bioprinting-verifies-bacteria-behaviour-models/
Good bid support this morning.
It may just be a day without a Pinnertest tweet...
Nothing on Edgar yet.
Looks like the market believes fair-value without financials is at .06 or so.
I'll take that...for now.